Evolus Announces Results From European Head-To-Head Filler Trial; European Lift Study Met The Primary Endpoint Of Non-Inferiority
Portfolio Pulse from Benzinga Newsdesk
Evolus, Inc. (NASDAQ:EOLS) announced its dermal filler product (Evolysse™/Estyme® Lift) showed statistical superiority over Restylane-L in a European study, meeting its primary endpoint of non-inferiority at 3 and 6 months. The company plans to launch the first-generation Cold HA Technology globally in 2025, with FDA filing expected in summer 2024. The study, which enrolled 45 patients, demonstrated the safety and effectiveness of the Evolysse™/Estyme® Lift filler. Additionally, Evolus has entered into exclusive distribution agreements with Symatese for the US and Europe, expanding its market by 78% to approximately $6 billion.
March 01, 2024 | 1:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Evolus, Inc. announced positive results from its European head-to-head filler trial, showing its Evolysse™/Estyme® Lift product's superiority over Restylane-L. The company is on track for a global launch in 2025, with FDA filing expected in 2024. Additionally, Evolus has expanded its market through exclusive distribution agreements, increasing its addressable market to approximately $6 billion.
The positive trial results and the strategic distribution agreements significantly bolster Evolus's market position and product portfolio, likely leading to increased investor confidence and potential stock price appreciation in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100